Updates are available Correction dated 2023-08-31
Click to view Correction: https://doi.org/10.1038/s41587-023-01942-1
-
Authors
Lareau, Caleb A. http://orcid.org/0000-0003-4179-4807
Ludwig, Leif S. http://orcid.org/0000-0002-2916-2164
Muus, Christoph http://orcid.org/0000-0003-2779-0893
Gohil, Satyen H.
Zhao, Tongtong
Chiang, Zachary
Pelka, Karin
Verboon, Jeffrey M.
Luo, Wendy
Christian, Elena
Rosebrock, Daniel
Getz, Gad http://orcid.org/0000-0002-0936-0753
Boland, Genevieve M.
Chen, Fei http://orcid.org/0000-0003-2308-3649
Buenrostro, Jason D. http://orcid.org/0000-0001-9958-3987
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Aryee, Martin J.
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Sankaran, Vijay G. http://orcid.org/0000-0003-0044-443X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01DK103794)
New York Stem Cell Foundation (NYSF-R-I48)
- License Information
-
More Information
Article History
Received: 20 January 2020
Accepted: 17 July 2020
First Online: 12 August 2020
Change Date: 31 August 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-023-01942-1
Competing interests
: The Broad Institute has filed for a patent related to lineage tracing using mtDNA mutations where C.A.L., L.S.L., C.M., J.D.B., A.R. and V.G.S. are named inventors. J.D.B. holds patents related to ATAC-seq. N.H. and C.J.W. are co-founders, equity holders and SAB members of Neon Therapeutics, Inc., and receive research funding from Pharmacyclics. G.G. receives research funding from IBM and Pharmacyclics. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific.
